JP2014521648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521648A5 JP2014521648A5 JP2014522917A JP2014522917A JP2014521648A5 JP 2014521648 A5 JP2014521648 A5 JP 2014521648A5 JP 2014522917 A JP2014522917 A JP 2014522917A JP 2014522917 A JP2014522917 A JP 2014522917A JP 2014521648 A5 JP2014521648 A5 JP 2014521648A5
- Authority
- JP
- Japan
- Prior art keywords
- retinal
- pharmaceutical composition
- pharmaceutically acceptable
- macular degeneration
- neuroprotection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010064930 age-related macular degeneration Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 208000008069 Geographic Atrophy Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004112 neuroprotection Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 229940126601 medicinal product Drugs 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 claims 2
- JHOJNZYPXCAPKL-UHFFFAOYSA-N 4-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-benzimidazol-5-amine Chemical group C1=CC=2NC=NC=2C(Br)=C1N=C1NCCN1 JHOJNZYPXCAPKL-UHFFFAOYSA-N 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000027073 Stargardt disease Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000012856 packing Methods 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000029977 White Dot Syndromes Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 210000003370 receptor cell Anatomy 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161510536P | 2011-07-22 | 2011-07-22 | |
| US201161510743P | 2011-07-22 | 2011-07-22 | |
| US61/510,536 | 2011-07-22 | ||
| US61/510,743 | 2011-07-22 | ||
| PCT/US2012/047777 WO2013016252A1 (en) | 2011-07-22 | 2012-07-22 | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521648A JP2014521648A (ja) | 2014-08-28 |
| JP2014521648A5 true JP2014521648A5 (cg-RX-API-DMAC7.html) | 2015-09-03 |
Family
ID=46599017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522917A Pending JP2014521648A (ja) | 2011-07-22 | 2012-07-22 | 網膜疾患を治療するための４−ブロモ−ｎ−（イミダゾリジン−２−イリデン）−１ｈ−ベンゾイミダゾール−５−アミンを含む医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130046003A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2734202A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014521648A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140097106A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103826631A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012287062A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014001538A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2842756A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL230582A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014000870A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014106328A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013016252A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0775134A4 (en) | 1994-08-04 | 1997-08-13 | Synaptic Pharma Corp | NEW BENZIMIDAZOLE DERIVATIVES |
| US6066675A (en) | 1996-09-13 | 2000-05-23 | The Regents Of The University Of California | Method for treatment of retinal diseases |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8293742B2 (en) * | 2008-08-01 | 2012-10-23 | Alpha Synergy Development, Inc. | Preferential vasoconstriction compositions and methods of use |
| CN102770135A (zh) * | 2010-01-21 | 2012-11-07 | 阿勒根公司 | 眼内压降低作用持续时间长的α-2肾上腺素能激动剂 |
-
2012
- 2012-07-20 US US13/555,070 patent/US20130046003A1/en not_active Abandoned
- 2012-07-22 JP JP2014522917A patent/JP2014521648A/ja active Pending
- 2012-07-22 MX MX2014000870A patent/MX2014000870A/es not_active Application Discontinuation
- 2012-07-22 BR BR112014001538A patent/BR112014001538A2/pt not_active IP Right Cessation
- 2012-07-22 RU RU2014106328/15A patent/RU2014106328A/ru not_active Application Discontinuation
- 2012-07-22 KR KR1020147004520A patent/KR20140097106A/ko not_active Withdrawn
- 2012-07-22 CA CA2842756A patent/CA2842756A1/en not_active Abandoned
- 2012-07-22 EP EP12741226.0A patent/EP2734202A1/en not_active Withdrawn
- 2012-07-22 CN CN201280046184.4A patent/CN103826631A/zh active Pending
- 2012-07-22 WO PCT/US2012/047777 patent/WO2013016252A1/en not_active Ceased
- 2012-07-22 AU AU2012287062A patent/AU2012287062A1/en not_active Abandoned
-
2014
- 2014-01-22 IL IL230582A patent/IL230582A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mayama | Calcium channels and their blockers in intraocular pressure and glaucoma | |
| JP2008538215A5 (cg-RX-API-DMAC7.html) | ||
| RU2017129247A (ru) | Способы и композиции для лечения болезни сухого глаза и других глазных заболеваний | |
| PH12017501097A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| Bravo-Osuna et al. | Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina | |
| FI3811943T3 (fi) | Yhdiste käytettäväksi silmäsairauksien hoidossa | |
| JP2005523316A5 (cg-RX-API-DMAC7.html) | ||
| JP2018506570A5 (cg-RX-API-DMAC7.html) | ||
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| RU2012151575A (ru) | Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин | |
| JP2020531511A5 (cg-RX-API-DMAC7.html) | ||
| IL293188B2 (en) | The compound varenicline for use as a medicament for treating dry eye, increasing tear production and treating ocular discomfort, and a pharmaceutical formulation comprising varenicline | |
| MX2021005077A (es) | Peptidos y composiciones farmaceuticas para tratar enfermedades oculares. | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| US20140358124A1 (en) | Approach to administering ocular medication | |
| HRP20241182T1 (hr) | Upotreba luteolin-7-o-glukozida ili luteolin-7-o-glukuronida u pripremi lijeka za ozljede oka | |
| JP2014521648A5 (cg-RX-API-DMAC7.html) | ||
| US20200383946A1 (en) | Lipoic acid formulations | |
| RU2016127357A (ru) | Модулятор сетр для применения в лечении заболеваний глаз | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| EA200970562A1 (ru) | Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы | |
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки | |
| WO2014204357A3 (ru) | Лекарственное средство для лечения кератоконуса | |
| RU2020124373A (ru) | Профилактический агент и/или терапевтический агент для катаракты, медицинский состав для предотвращения и/или лечения катаракты, применение ppar-активатора для тех же целей и глазные капли | |
| RU2008107696A (ru) | Неинвазивная система доставки лекарственного средства к ткани заднего сегмента глаза с применением твердой композиции |